Overview
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
Eligibility
Inclusion Criteria:
- Have Body Mass Index (BMI) at screening of the following:
- 30 kilogram per square meter (kg/m2) OR
- 27 kg/m2 with at least one of the following weight-related health conditions at screening:
- high blood pressure
- dyslipidemia
- obstructive sleep apnea, or
- heart disease
- Have a stable body weight (\<5% body weight change) for 90 days prior to screening.
- Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight
Exclusion Criteria:
- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
- Have type 1 diabetes or type 2 diabetes
- Have had within 90 days prior to screening:
- heart attack
- stroke
- coronary artery revascularization
- unstable angina, or
- hospitalization due to congestive heart failure
- Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
- Have taken medications or alternative remedies intended for weight loss within 90 days of screening